<DOC>
	<DOCNO>NCT02118571</DOCNO>
	<brief_summary>The objective protocol develop item patient-reported outcome ( PRO ) measure assess patient 's perspective subjective experience cognitive impairment associate schizophrenia ( CIAS ) .</brief_summary>
	<brief_title>Schizophrenia Cognition Scale Development</brief_title>
	<detailed_description>Cognitive impairment associate schizophrenia ( CIAS ) show strong predictor functional impairment among people schizophrenia associate poor response psychosocial intervention , employment status , social functioning . Because subjective experience CIAS likely associate patient burden , distress , motivation treatment , important experience assess reliable valid manner perspective patient 's self report . No exist instrument ass CIAS develop patient input directly qualitative experience impaired cognition item generation stage , accordance FDA guidance patient-reported outcome ( PRO ) measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1 . Patients establish diagnosis schizophrenia ( confirm Structured Clinical Interview DSMIV [ full version Clinical Trial version ] either perform part study screen process document medical record within 2 year prior study ) follow clinical feature : ) Clinically stable residual ( nonacute ) phase illness least 8 week b ) Maintained current antipsychotic concomitant psychotropic medication least 6 week current dose least 2 week c ) Have `` moderate '' severity rating hallucination delusion ( e.g . Positive Negative Syndrome Scale [ PANSS ] item score &lt; 5 ) Have `` moderate '' severity rating positive formal think disorder ( e.g . Positive Negative Syndrome Scale [ PANSS ] conceptual disorganization item score &lt; 5 ) e ) Have `` moderate '' severity rating negative symptom ( e.g. , Positive Negative Syndrome Scalenegative syndrome total score &lt; 21 ) f ) Have minimal level depressive symptom ( e.g . Calgary Depression Scale total score &lt; 10 ) ; , eligibility wait list , moderate level depressive symptom ( e.g. , Calgary Depression Scale total score 10 15 ) 2 . Male female patient age 18 55 year 3 . Exhibits reliability , physiologic capability , educational level sufficient comply protocol procedure . 4 . Able provide inform consent 1 . Patient currently treat two antipsychotic medication 2 . Patient 's cognitive impairment severity compromise ability participant participate meaningfully semistructured interview , clinical judgment investigator 3 . Any suicidal ideation type 4 5 CSSRS past 3 month ( i.e . active suicidal think intent without specific plan , active suicidal think plan intent ) 4 . Nonpsychiatric disorder central nervous system ( include limit kind seizure , stroke , traumatic brain injury ) 5 . Any clinical condition , opinion investigator , would jeopardize patient 's safety participate study 6 . In 6 month prior , meet criterion dependence abuse accord DSM V opinion investigator . 7 . Participation another trial investigational drug procedure within 30 day prior screen previous participation BI 409306 study 8 . Unable speak read English</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>